However, a recent meta-analysis demonstrated that treatment with a SGLT2 inhibitor was associated with significant improvements in plasma NT-proBNP concentrations in patients with T2D, irrespective of the presence of CHF [33]. Here, NPPB is linked to type 2 diabetes mellitus.